Class: Vaccine, bacterial
- Injection 48 mcg
- Injection 50 mcg
Induces production of bactericidal antibodies specific to capsular polysaccharides of serogroups A, C, Y, and W-135.
Indications and UsageMenactra
Active immunization of children and adults 2 to 55 yr of age against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.Menomune
Active immunization against invasive meningococcal disease caused by serogroups A, C, Y, and W-135; may be used to prevent and control outbreaks of serogroup C meningococcal disease.
Hypersensitivity to dry natural rubber latex; hypersensitivity to any component of the product, including diphtheria toxoid; known history of Guillain-Barré syndrome; life-threatening reaction after previous administration of a vaccine containing similar components.Menomune
Known sensitivity to thimerosal or any component of the vaccine. Defer immunization during any acute illness.
Dosage and AdministrationMenactra
Adults and children 2 to 55 yr of age
IM Single 0.5 mL dose, preferably in the deltoid region.Menomune
Adults and children 2 yr of age and older
Subcutaneous Single 0.5 mL dose. Revaccination with a single 0.5 mL dose may be indicated for persons at high risk of infection, particularly children who were first vaccinated when they were younger than 4 yr of age.
- Do not mix meningococcal vaccine with any vaccine in the same syringe. Separate injection sites and different syringes should be used in case of coadministration.
- Menactra is for IM use only. Do not administer IV, subcutaneously, or intradermally.
- Menomune is for subcutaneous use only. Do not administer IM, IV, or intradermally.
Store vials in refrigerator (36° to 46°F). Protect from freezing. Do not use vaccine if it has been frozen.Menomune
Store at 35° to 46°F. Discard remainder of multidose vials within 35 days of reconstitution. Use single-dose vial within 30 min after reconstitution.
Drug InteractionsImmunosuppressive therapy
An adequate immunologic response may not be obtained.Whole-cell pertussis, whole-cell typhoid vaccines
Do not coadminister with Menomune because of combined endotoxin content.
Laboratory Test Interactions
None well documented.
Headache (42%); fatigue (35%); malaise (24%); irritability (12%); drowsiness (11%); acute disseminated encephalomyelitis, facial palsy, Guillain-Barré Syndrome, transverse myelitis, vasovagal syncope (postmarketing).
Rash (3%); urticaria (postmarketing).
Diarrhea (16%); anorexia (12%); vomiting (3%).
Pain (59%); tenderness (36%); redness (22%); induration (19%); swelling (17%); erythema (4%).
Arthralgia (20%); myalgia (postmarketing).
Chills (10%); fever (5%).
Category C .
Safety and efficacy not established in children younger than 2 yr of age.
Safety and efficacy not established in adults older than 55 yr of age.
Vaccine and vaccine components can cause hypersensitivity reactions.
Risk of Guillain-Barré Syndrome following Menactra vaccination may be increased. Persons with a history of Guillain-Barré Syndrome should not receive Menactra vaccine.
Dry natural latex rubber is contained in the vial stopper.
- Advise patient or caregiver that vaccine will be prepared and administered by health care provider.
- Review potential benefits and risks of vaccine with patient or caregiver and provide vaccine information statements for review.
- Advise patient or caregiver that pain at the injection site, headache, fever, general body discomfort, and joint pain can occur, and to use nonnarcotic analgesic and antipyretic (eg, ibuprofen) agents for symptomatic relief. Advise patient or caregiver to report severe, persistent, or unusual or unexplained symptoms to health care provider.
Copyright © 2009 Wolters Kluwer Health.